Thai female patients aged 18-65 years old with bilateral symmetrical malar type melasma Melasma, picosecond laser, 1064 nm, azelaic acid
Conditions
Interventions
Each patient treated by low fluence 1064-nm Nd:YAG picosecond laser every 2 weeks for 3 sessions on the right side of the face. Patients have to apply 20% azelaic acid cream twice daily to the melasma
1064-nm Nd:YAG picosecond laser with azelaic acid side,azelaic acid side
Sponsors
Institute of Dermatology, Bangkok, Thailand
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Thai female patients 2) Aged 18-65 years old 3) Diagnosed with bilateral symmetrical malar type melasma at the face 4) Can be able to attend and willing to be a subject in this study including being able to give a consent
Exclusion criteria
Exclusion criteria: 1) Taking oral contraceptive pills or receiving hormone replacement 2) In the period of pregnancy or lactation 3) Have underlying disease of autoimmune diseases such as SLE 4) Have underlying disease of thyroid diseases 5) Allergy to azelaic acid or preservatives in topical melasma treatment 6) Have a laser treatment on the face within 6 months before the study 7) Using topical melasma treatments such as kojic acid, hydroquinone, alpha arbutin and whitening agents within 4 weeks before the study 8) Treated melasma by chemical peeling agents within 3 months before the study 9) Using tranexamic acid or vitamin C within 3 months before the study 10) Taking or applying retinoid within 12 months before the study 11) Having an active asthma 12) Having a history of using antiepileptic drugs 13) Having skin infections or any other skin disease, for example, allergic dermatitis, cellulitis, erysipelas, herpes simplex and herpes zoster infection on the face
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma severity At baseline, 8 weeks, 12 weeks and 16 weeks after the baseline Hemi-Melasma Area and Severity Index | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician global assessment At 8 weeks, 12 weeks and 16 weeks after the baseline Physician global assessment scores,Patient satisfaction At 8 weeks, 12 weeks and 16 weeks after the baseline Patient satisfaction scores ,Sides effects At baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks after the baseline Sides effects report | — |
Countries
Thailand
Contacts
Public ContactNatthika Klaisung
Institute of Dermatology, Bangkok, Thailand
Outcome results
None listed